Main Causes of Lower eGFR
A lower eGFR results from either chronic kidney disease progression (most commonly from diabetes, hypertension, and glomerular diseases) or acute kidney injury from volume depletion, medications affecting renal hemodynamics, or renal hypoperfusion states.
Primary Chronic Causes
Diabetic Kidney Disease
Diabetic kidney disease is the leading cause of chronic eGFR decline, affecting 20-40% of diabetic patients 1, 2. This manifests as progressive albuminuria (UACR ≥30 mg/g) followed by declining eGFR, typically with concurrent diabetic retinopathy in type 1 diabetes 1. The natural history involves:
- Initial hyperfiltration (eGFR >90 mL/min/1.73 m²)
- Progressive decline averaging 2-3 mL/min/1.73 m²/year in heart failure patients (compared to 1 mL/min/1.73 m²/year in general population) 3
- Accelerated decline (>5 mL/min/1.73 m²/year) indicates severe progression requiring urgent intervention 3
Hypertensive Nephrosclerosis
Elevated systolic blood pressure is the strongest modifiable risk factor for eGFR decline after albuminuria 4. Each increment in systolic blood pressure accelerates GFR loss through glomerular hyperfiltration and microvascular damage 4. Left ventricular diastolic dysfunction and reduced ejection fraction compound this effect through cardiorenal mechanisms 4.
Glomerular and Microvascular Disease
Microcirculation impairment substantially contributes to glomerular filtration loss, even more than large vessel stenosis 5. In renal artery stenosis, plasma cystatin C and urinary microalbumin show strong inverse correlations with eGFR (r = -0.713 and r = -0.580 respectively), whereas stenosis severity itself poorly predicts eGFR 5.
Acute Causes and Precipitants
Volume Depletion and Hypoperfusion
Acute kidney injury from volume depletion, whether from diuretics, diarrhea, or inadequate intake, causes rapid eGFR decline that is typically reversible 1, 6. Heart failure with elevated central venous pressure creates renal venous congestion, reducing the pressure gradient between afferent and efferent arterioles 7.
Medication-Induced Changes
Expected Hemodynamic Changes
ACE inhibitors and ARBs cause an expected 10-20% acute eGFR decline through efferent arteriolar vasodilation, which is therapeutic and associated with better long-term outcomes 8, 3. This should not be confused with acute kidney injury 1. Similarly, SGLT2 inhibitors cause a temporary 15-25% eGFR decrease that resolves in 1-3 months and does not represent true kidney injury 9.
Nephrotoxic Medications
NSAIDs, including COX-2 inhibitors, precipitate acute kidney injury by blocking compensatory prostaglandin-mediated vasodilation 6, 8. Cyclosporine and certain antibiotics directly damage tubules 6.
Cardiorenal Syndrome
In heart failure, reduced cardiac output decreases renal perfusion while right ventricular dilation increases renal venous pressure—both mechanisms lower eGFR 7. Type 2 cardiorenal syndrome (chronic heart failure causing CKD) represents progressive bidirectional deterioration 7.
Critical Risk Factors for Accelerated Decline
Based on time-averaged analysis, the strongest predictors of rapid eGFR decline (≥25% per year) are 10:
- Proteinuria (strongest association)
- Hyperphosphatemia
- Anemia (low hemoglobin)
- Hypoalbuminemia
Male sex, younger age at baseline, and elevated uric acid also accelerate decline 10.
Important Clinical Pitfalls
Do Not Confuse Therapeutic eGFR Changes with AKI
Up to 30% serum creatinine increase with RAS blockers does not increase mortality or progressive kidney disease—this represents beneficial reversal of hyperfiltration 1, 8. Continue therapy unless eGFR drops >30% within 3 months, which suggests renal artery stenosis or severe volume depletion 9, 8.
Recognize High-Risk Scenarios for True AKI
Suspect acute kidney injury (not therapeutic change) when 1, 8:
- Rapid, large eGFR fall (>30% acutely)
- Concurrent NSAID use
- Severe volume depletion or hypotension
- Bilateral renal artery stenosis
- Combination of diuretics, ACE inhibitors/ARBs, and SGLT2 inhibitors without volume monitoring
Age and Gender Considerations
Older adults and females are underrepresented in kidney failure registries because they more commonly die before requiring dialysis despite meeting eGFR criteria for kidney failure 11. The 5-year risk of death without KRT is 34% for those meeting eGFR <15 criteria 11.
Staging and Clinical Thresholds
An eGFR <60 mL/min/1.73 m² defines CKD stages 3-5 and requires medication dose adjustments 12, 1. Stage 3 subdivides into:
- 3a: 45-59 mL/min/1.73 m² (mild-moderate decrease)
- 3b: 30-44 mL/min/1.73 m² (moderate-severe decrease)
- Stage 4: 15-29 mL/min/1.73 m² (severe decrease, prepare for renal replacement)
- Stage 5: <15 mL/min/1.73 m² (kidney failure) 2
Renal replacement therapy should be considered at eGFR <30 mL/min/1.73 m² 2.